Disclosed are a near-infrared absorbing composition, an optical structure, and a camera module and an electronic device including the same. The near-infrared absorbing composition includes a copper complex represented by Chemical Formula 1. ##STR00001##
Definitions of Chemical Formula 1 are the same as described in the detailed description.

The present disclosure provides certain N-Acylethanolamide derivatives, and uses relating thereto.

Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Provided is a medical suture thread which is less likely to remain curled or is easily uncurled from a curled state. The medical suture thread 100 includes a core thread 110 and an outer thread 120. The core thread 110 includes multiple twisted ultrafine threads 111, and is arranged at a center portion of the medical suture thread 100. In the ultrafine thread 111, an inner-filament cover layer 112 made of 2-methacryloyloxyethyl phosphorylcholine (MPC) is formed on an outer surface of a filament 111a. The outer thread 120 is formed to be braided with multiple ultrafine threads 121, and covers an outer surface of the core thread 110. In the ultrafine thread 121, an outer-filament cover layer 122 made of MPC is formed on an outer surface of a filament 121a. The inner-filament cover layer 112 and the outer-filament cover layer 122 are respectively formed on the outer surfaces of the filaments 111a, 121a within a weight range of equal to or greater than 0.05% and less than 0.3% with respect to the total weight of each of the filaments 111a, 121a, respectively.

An object is to provide a zwitterionic compound having an excellent protein adsorption inhibitory effect. The zwitterionic compound is a polymer comprising a unit represented by the following formula (1):

##STR00001##

wherein R.sup.1 is a hydrogen atom or a methyl group, R.sup.2 is OH or O.sup.−, X.sup.1 is —O— or —N(Q.sup.1)-, Q.sup.1 is a hydrogen atom or a C.sub.1-6 alkyl group, m is an integer of 1 to 12, and n is an integer of 1 to 4.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is —OH or —OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

The present invention relates to the field of luminescent crystals (LCs), and more specifically to Quantum Dots (QDs) of formula A.sup.1.sub.aM.sup.2.sub.bX.sub.c, wherein the substituents are as defined in the specification. The invention provides methods of manufacturing such luminescent crystals, particularly by dispersing suitable starting materials in the presence of a liquid and by the aid of milling balls; to compositions comprising luminescent crystals and to electronic devices, decorative coatings; and to components comprising luminescent crystals.

Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor is cell impermeable. Also provided are compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of a ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject either before or after administering an ENPP1 inhibitor. The radiation therapy can be administered at a dosage and/or frequency effective to reduce radiation damage to the subject. In certain cases, the method is performed in combination with a chemotherapeutic agent, or a checkpoint inhibitor, or both.

The invention relates to a compound of following formula (I), and also to the addition salts thereof with an organic or mineral base, the solvates such as hydrates and the mixtures thereof; to the use thereof as a surfactant, wetting agent, detergent, emulsifier, dispersant, corrosion inhibitor, plasticizer, sequestering agent, ionic liquid, stabilizer, lubricant, bitumen additive, gelling agent in oils, flotation collector for ores, adjuvant in the manufacture of plastic objects, anti-static agent, additive for fertiliser coverings and for enhanced oil recovery, and also to the compositions comprising at least one compound of formula (I) and/or a salt thereof, alone or as a mixture. ##STR00001##

This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.